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Abstract
Background: Compared to blood or urine, drugs can be detected for much longer periods in the long hair of
horses. The aim of this study was to establish and validate a highly sensitive liquid chromatography tandem mass
spectrometry (LC-MS/MS) method for the detection and quantification of frequently prescribed opioids, sedatives
and non-steroidal anti-inflammatory agents in the mane and tail hair of horses. Based on an average growth rate of
about 2 cm per month, times of administration reported by horse owners or veterinary physicians were related to
drug localizations in hair. Hair samples were collected from ten horses that received drug treatments and analyzed
in segments of 2, 4 or 6 cm in length. Hair segments were decontaminated, cut into fragments and methanol-extracted
under sonication. The extracts were analyzed by LC-MS/MS for 13 commonly used drugs using the validated procedure.
Deuterated analogs were included as internal standards.
Results: Analytes were detected in hair samples with a length of up to 70 cm. Fourteen out of 16 hair samples were
positive for at least one of the tested drugs. Segmentation allowed for time-resolved monitoring of periods of 1 to
3 months of drug administration. Concentrations in dark hair reached a maximum of 4.0 pg/mg for butorphanol, 6.
0 pg/mg for tramadol, 1.4 pg/mg for morphine, 1.8 pg/mg for detomidine, 1.2 pg/mg for acepromazine, 39 pg/mg for
flunixin, 5.0 pg/mg for firocoxib, and 3’600 pg/mg for phenylbutazone. Only trace amounts of meloxicam were detected.
Drug detection correlated well with the reported period of medical treatment. No analytes were detected in the
light-colored mane and tail hair samples from one horse despite preceding administrations of acepromazine and
phenylbutazone.
Conclusion: This study describes a sensitive and selective technique suitable for the validated detection and
quantification of frequently prescribed veterinary drugs in horse hair. The segmental method can be applied
for time-resolved long-term retrospective drug monitoring, for example in prepurchase examinations of horses
as drug detection in hair can prove preceding medical treatments.
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Background
Horse hair analysis has gained increasing interest for the
monitoring of veterinary drugs, hormones, nutrients,
trace elements and contaminants [1–7]. In contrast to
blood and urine, hair provides a long-term historical rec-
ord of drug exposure that may be useful for applications
in sports anti-doping control programs, pre-purchase
examination of horses and examinations for insurance
purposes [2]. Other advantages of hair analyses include
the non-invasive probing as well as drug-stability in hair
and easy shipping of samples [8]. The growth of tempor-
ary hair of the coat changes with seasons whereas the
permanent mane and tail hair grows continuously with
relatively constant rates reported in the range from 1.7
to 2.5 cm per month [1, 2, 9, 10]. Therefore, samples of
long hair can be segmented to narrow down the corre-
sponding times of drug exposure [2, 11].
So far, detection in horse hair has been demonstrated for
morphine [1], clenbuterol [3], anabolic steroids [4, 7, 9],
antimicrobial agents [12], diazepam [13], cortisol [14],
arsenic [6] and selenium [15]. The aim of this study was
twofold. The first goal was to extend the use of mane and
tail hair as a matrix for the monitoring of sedative, anal-
gesic and anti-inflammatory drugs that are frequently pre-
scribed to horses. The second goal was to compare closely
the analytical findings in hair segments with the corre-
sponding times of drug administration. To that end, a
highly sensitive liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) method was established, validated
and applied to mane and tail hair samples of 10 horses
with a known history of pharmacologic treatments.
Methods
Study design and sample collection
The study included ten horses with documented admin-
istration of at least one of the investigated drugs before
sampling. All horse owners provided informed consent
to participate in the study. Sixteen mane and nine tail
hair samples were collected by horse owners or veteri-
narians. One tail hair sample was collected post-
mortem. The sampling method was adapted from guide-
lines of the Society of Hair Testing (SoHT) [11]. A hair
lock was fixed with the hair strands equally aligned using
a string and cut precisely close to the skin. The lock was
wrapped in aluminum foil with the proximal ends
aligned for clear identification. Samples were stored at
room temperature under dry conditions and in the dark.
Individual data on drug administration, hair type and
color of each horse are reported in Table 1.
Analytical standards and chemicals
Morphine, morphine-d3, tramadol,
13C-tramadol-d3,
buprenorphine-d4, chlorpromazine-d3, and phenylbuta-
zone were obtained as solutions from Sigma-Aldrich
Chemie GmbH (Buchs, Switzerland). Butorphanol and
buprenorphine were obtained as solutions from Resea-
Chem GmbH (Burgdorf, Switzerland) and Lipomed AG
(Arlesheim, Switzerland), respectively. Ketoprofen-d3 and
phenylbutazone-(diphenyl13C12) were purchased as pow-
ders Sigma-Aldrich Chemie GmbH (Buchs, Switzerland).
Detomidine, acepromazine, meloxicam, ketoprofen, chlor-
promazine, flunixin and fluphenazine were analytical
standards available as powders in the authors’ laboratory.
All solvents and other chemicals were purchased from
Sigma-Aldrich Chemie GmbH (Buchs, Switzerland). All
standards were dissolved in methanol, except for meloxi-
cam that was dissolved in dimethylformamide, to yield
stocks of 1 mg/ml. Firocoxib was obtained as an injectable
for veterinary use. Chromatography-grade water used for
LC-MS/MS analysis was processed by a PURELAB
Option-Q system by ELGA LabWater (Labtec Services
AG, Villmergen, Switzerland).
Table 1 Drug treatment of the horses (relative to time of
sample collection) and characteristics of hair samples
Horse Reported
drug (s)
Time before sampling Hair samples
(length, color)
P01 Acepromazine 2 months Mane (16 cm, light)
Tail (28 cm, light)
Phenylbutazone 3 and 9 months
P02 Butorphanol 22 months Tail (70 cm, dark)
Detomidine With euthanasia
Flunixin 1 day and 22 months
P03 Flunixin 8 months Mane (16 cm, dark)
Tail (28 cm, dark)
Ketoprofen 8 months
P04 Flunixin 9 months Mane (16 cm, dark)
Tail (26 cm, dark)
Ketoprofen 9 months
Phenylbutazone 10 months
P05 Flunixin 7 months Mane (16 cm, dark)
Tail (28 cm, dark)
P06 Acepromazine 15 months Tail (68 cm, dark)
Butorphanol 17 months
Phenylbutazone 8 months
P07 Flunixin 2 and 4 months Mane (24 cm, dark)
Tail (26 cm, dark)
Phenylbutazone 2 and 4 months
P08 Butorphanol 6 months Mane (20 cm, dark)
Detomidine 6 months
Phenylbutazone 10 months
Tramadol 6 months
P09 Flunixin 1 week Mane (24 cm, white)
Tail (24 cm, dark)
Phenylbutazone 1 week
P10 Butorphanol 8 months Tail (44 cm, dark)
Firocoxib 10 months
Meloxicam 10 months
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Preparation of working solutions
Spiking solutions for calibrators and quality control (QC)
samples were prepared in methanol to yield concentra-
tions comparable to those found in hair. An internal
standard (IS) solution with the following concentrations
was prepared in methanol: morphine-d3 (15 ng/ml),
13C-
tramadol-d3 (8.0 ng/ml), buprenorphine-d4 (20 ng/ml),
ketoprofen-d3 (10 ng/ml), chlorpromazine-d3 (10 ng/ml)
and phenylbutazone-(diphenyl13C12) (30 ng/ml).
Hair sample preparation
Mane and tail hair samples were cut into 2- or 4-cm
segments; one very long hair sample of 70 cm was ana-
lyzed in 6-cm segments. For a thorough decontamin-
ation according to the laboratory standard procedure for
forensic hair analysis, 10 mg of hair were washed once
with 5 mL deionized water and twice with 5 mL acetone
for 3 min each. After drying at room temperature, hair
segments were chopped in snippets with scissors. For
extraction, 100 μl IS solution and 1900 μl methanol were
added and samples were sonicated for 4 h at 50 °C. After
centrifugation for 7.5 min at 10,000 g, 1500 μl of the
clear solution was transferred into a vial for evaporation
under a stream of nitrogen at 40 °C. For injection into
the LC-MS/MS system, the residue was reconstituted
in 60 μl 5 mM ammonium formatea (pH 3) with 10 %
(v/v) methanol.
LC-MS/MS parameters
Analytes were separated on a C18 column (Phenomenex
Kinetex 2.6 μm C18 column, 50 × 2.1 mm, Brechbühler
AG, Schlieren, Switzerland) using a high-performance
LC system (Ultimate 3000 HPLC system, Thermo Fisher
Scientific AG, Reinach, Switzerland) and detected by a
linear ion trap triple quadrupole mass spectrometer (Ap-
plied Biosystems 5500 Q Trap with Analyst software,
Sciex, Darmstadt, Germany). The mobile phase con-
sisted of 5 mM ammonium formate buffer (pH 3; eluent
A) and methanol containing 5 mM ammonium formate
(eluent B). The following gradient was used: 10 to 50 %
B from 0 to 3 min, 50 % B from 3 to 10 min, 50 to 90 %
B from 10 to 10.5 min and 90 % B from 10.5 to
11.5 min. The flow rate was 0.35 ml/min. The column
temperature was 35 °C and injection volumes were
10 μl. The MS instrument was operated in positive elec-
trospray ionization mode. Three specific multiple reac-
tion monitoring (MRM) transitions per substance were
analyzed, but for detomidine only two transitions could
be recorded (Table 2). Quantification was achieved using
the most abundant transition of each precursor to the
respective product ion. Criteria for positive identification
were the matching retention time, three specific MRM
transitions (one served as quantifier and two served as
qualifier), and the matching relative ion intensities of
MRM transitions (qualifier-to-quantifier) which were de-
termined from calibrators (n = 10 each) (Table 2). The
tolerance level for percent deviations of relative inten-
sities of MRM transitions was ±30 % [16]. The absence
of interfering peaks was verified for all analytes in blank
samples and after addition of the IS solution.
Method validation
The method was validated for selectivity, limit of detec-
tion (LOD), lower limit of quantification (LLOQ), linear-
ity of calibration, accuracy, intra-day and inter-day
precision, and matrix effects based on the Guidelines for
Quality Control in Forensic-Toxicological Analyses
[17, 18]. All validation parameters were assessed with
drug-free hair samples (blank hair) which were obtained
from horses that had never received medications. Drug-
free hair was spiked with 100 μl IS solution and 100 μl
calibrator or QC solution. The calibration line was calcu-
lated using a weighted [1/x, x = f (concentration)] linear
regression model. Calibration curves with seven calibra-
tors were prepared for eight days. LOD was defined as the
lowest concentration with a peak height showing a signal-
to-noise ratio of at least 3:1 in the chromatogram,
(Table 3). The LLOQ showing a signal-to-noise of at least
10:1 was chosen as the lowest calibrator concentration;
LLOQ levels ranged from 0.1 to 5 pg/mg, except for
phenylbutazone for which an LLOQ of 25 pg/mg was de-
termined. Accuracy and precision were determined via
daily calibration curves over eight days by analyzing
duplicate QC samples at low, medium, and high con-
centrations (Table 3). The accepted intervals for preci-
sion were ± 15 % (±20 % at LLOQ) for bias and
standard deviation of the nominal concentration. Proc-
essed sample stability in the auto-sampler at room
temperature was tested by pooling extracts prepared at
these low and high concentrations. Six aliquots were
injected in the LC-MS/MS system every 2 h over 18 h.
Further stability studies were not included as samples
were tested immediately after their preparation. Matrix
effects were studied with hair samples of different
sources as previously proposed [17, 19]: the peak area
of analytes in blank hair samples of different horses
(n = 5) spiked after the extraction was divided by the
mean peak area of analytes in neat standard solutions
(n = 5) at the same concentration level and multiplied
by 100. Values below or above 100 indicate ion sup-
pression or ion enhancement resulting in diminished
or increased signal intensities.
Results
Method validation
An LC-MS/MS method was developed for the detection
and quantification of 13 sedative, analgesic and anti-
inflammatory drugs commonly used in horses. A
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Table 2 LC-MS/MS parameters
Analyte/internal standard Precursor ion
(m/z)
Product ion
(m/z)
Relative ion intensities
(mean) ± rSD (%)a
RT (min) DP (V) EP (V) CE (V) CxP (V)
Morphine 286.1 152.1 0.7 ± 16 0.6 156 10 81 14
128.1 0.6 156 10 79 16
165.1 0.6 156 10 57 16
Tramadol 264.05 58.0 0.32 ± 6.2 3.4 46 10 17 10
58.5 3.4 46 10 33 8
42.0 3.4 46 10 115 20
Detomidine 187.09 81.1 0.23 ± 7.7 3.9 101 10 25 8
54.1 3.9 101 10 55 8
Butorphanol 328.17 310.2 0.15 ± 3.6 4.2 101 10 33 22
157.0 4.2 101 10 59 12
131.1 4.2 101 10 65 12
Buprenorphine 468.24 55.1 0.05 ± 12 5.1 1 10 101 6
41.1 5.1 1 10 129 4
115.1 5.1 1 10 129 6
Acepromazine 327.04 86.0 0.99 ± 5.6 5.5 81 10 25 10
58.0 5.5 81 10 65 8
222.1 5.5 81 10 53 16
Firocoxib 337.02 283.1 0.81 ± 7.1 5.6 101 10 13 16
130.1 5.6 101 10 41 12
237.0 5.6 101 10 23 20
Meloxicam 351.96 115.0 0.37 ± 7.0 6.3 126 10 25 10
141.0 6.3 126 10 27 12
73.0 6.3 126 10 75 12
Chlorpromazine 319.26 58.1 0.89 ± 4.2 6.7 86 10 67 12
86.1 6.7 86 10 25 8
214.0 6.7 86 10 57 20
Ketoprofen 255.08 77.0 0.93 ± 6.7 6.7 131 10 61 12
104.9 6.7 131 10 33 12
51.1 6.7 131 10 99 8
Flunixin 297.03 278.9 0.38 ± 3.1 7.3 111 10 33 24
264.0 7.3 111 10 47 22
236.1 7.3 111 10 57 16
Fluphenazine 438.22 171.0 0.71 ± 2.8 9.3 56 10 37 20
143.1 9.3 56 10 37 18
70.0 9.3 56 10 67 10
Phenylbutazone 309.15 77.0 0.51 ± 9.6 9.5 216 10 75 12
160.1 9.5 216 10 29 14
120.0 9.5 216 10 27 10
Morphine-d3 289.02 201.0 0.6 156 10 35 16
152.1 0.6 156 10 75 18
13C-Tramadol-d3 268.07 58.0 3.4 46 10 49 14
42.1 3.4 46 10 113 20
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representative chromatogram including all analytes is
given in Fig. 1. The method, validated according to the
Guidelines for Quality Control in Forensic-Toxicological
Analyses [17, 18], was selective and very sensitive for all
analytes. The detection of buprenorphine, butorphanol,
detomidine, firocoxib, flunixin, ketoprofen, meloxicam,
morphine and phenylbutazone fulfilled all validation cri-
teria (Table 4). For chlorpromazine and tramadol, matrix
effects exceeded the limits of ± 25 % standard deviation,
but this was compensated by the inclusion of deuterated
standards. The detection of acepromazine and fluphen-
azine displayed deviations in accuracy as well as precision,
and variable matrix effects were observed. However, inclu-
sion of labeled analogs of the two compounds allowed for
comparisons between samples from the same horse. For
all other drugs, the method was successfully validated and
proven to be suitable for the comparison of hair samples
from different horses.
Detection of opioids
Butorphanol was detected in the hair of four out of five
horses having received the drug. The concentrations
ranged from below LLOQ to 4.0 pg/mg. In horse P02,
repeated administrations of butorphanol were reported
22 months before sample collection and the highest con-
centration (4.0 pg/mg) was detected in a tail hair seg-
ment corresponding to a distance from the skin of 36 to
42 cm (Fig. 2a). In horse P08, a single application of
butorphanol 6 months before sampling resulted in drug
concentrations in tail hair of 0.9–2.3 pg/mg spread
across a distance of 6–16 cm from the skin. In many
cases, more drugs were found in hair than reported to
have been administered. For example, butorphanol was
detected in multiple 2-cm segments of the mane and tail
hair of horse P07 (peak concentration of 3.6 pg/mg at a
distance of 18–20 cm from the skin) and P10 (peak of
0.6 pg/mg at 22–24 cm from the skin), although
Table 2 LC-MS/MS parameters (Continued)
Buprenorphine-d4 472.26 59.0 5.1 1 10 107 6
400.1 5.1 1 10 53 2
Chlorpromazine-d3 322.04 89.1 6.7 51 10 25 10
61.1 6.7 51 10 59 8
Ketoprofen-d3 258.09 212.1 6.7 121 10 19 14
105.0 6.7 121 10 31 10
13C12-Phenylbutazone 321.11 166.2 9.5 76 10 29 14
55.1 9.5 76 10 129 8
MRM (multiple reaction monitoring mode) transitions with precursor and product ions, relative ion intensities of MRM transitions (qualifier-to-quantifier);
RT retention time, DP declustering potential, EP entrance potential, CE collision energy, CxP collision cell exit potential. MRM transitions used as quantifiers
are given in bold
adetermined from calibrators (n = 10, per analyte)
Table 3 Analyte concentrations in method validation: for limit of detection (LOD), lower limit of quantification (LLOQ), calibration
range and quality control (QC) samples
Analyte LOD (pg/mg) LLOQ (pg/mg) Cal. range (pg/mg) QC low (pg/mg) QC medium (pg/mg) QC high (pg/mg)
Morphine 0.1 0.6 0.6–840 0.585 270 555
Tramadol 0.1 0.5 0.5–100 0.48 30 68
Detomidine 0.1 0.6 0.6–36 0.585 11 24
Butorphanol 0.1 0.5 0.5–50 0.48 15 33
Buprenorphine 1 2 2–800 1.95 225 540
Acepromazine 0.05 0.1 0.1–150 0.098 45 101
Firocoxib 0.5 1 1–740 0.975 225 495
Meloxicam 0.5 2 2–280 1.95 90 188
Ketoprofen 1 5 5–420 4.8 135 278
Chlorpromazine 0.5 1 1–280 0.975 90 189
Flunixin 0.05 0.1 0.1–66 0.098 223 44
Fluphenazine 0.5 1 1–600 0.975 180 405
Phenylbutazone 10 25 25–7000 24 2250 4650
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administration of this drug was not reported. However,
the presence of butorphanol was not demonstrated in
the dark tail hair of horse P06 treated once 17 months
before sample collection.
A single dose of tramadol was administered to horse
P08 around 6 months before sample collection. This
treatment resulted in a distinctive analyte peak (6 pg/
mg) in a unique 2-cm segment of tail hair located 8–
10 cm from the skin (Fig. 2b). A distinctive peak of the
same drug (1.1 pg/mg) was also found in the tail hair of
horse P02 but without any documentation of previous
tramadol use. Morphine was present in the tail hair sam-
ple of horse P02 at concentrations of up to 1.4 pg/mg,
although medication with this analgesic drug had not
been recorded. There was no report of buprenorphine
administration and, accordingly, all samples were nega-
tive for this substance.
Detection of sedatives
A single detomidine application was given to horse P02
on the day of euthanasia. This resulted in detection of
traces of the drug around or below the LLOQ in all
tested mane and tail hair segments, indicating an exter-
nal contamination by sweat or other biological fluids.
Detomidine was also detected in the mane hair of horse
P07, with maximum levels (1.8 pg/mg) at a distance of
4–6 cm from the skin, although administration of this
drug was not reported. On the other hand, a single dose
of detomidine 6 months before sampling could not be
detected in the dark mane hair of horse P08. Aceproma-
zine, given to horse P06 around 15–16 months before
sampling, was retrieved at concentrations of 0.5–1.2 pg/
mg in tail hair segments corresponding to a distance of
8–40 cm from the skin (Fig. 2c). There was no report of
chlorpromazine and fluphenazine administration and
none of the samples contained these drugs.
Detection of non-steroidal anti-inflammatory agents
All hair samples of the four horses with reported flu-
nixin administration were positive for this common anti-
inflammatory agent, the highest detected concentration
being 39 pg/mg. A sharp peak of flunixin deposition was
observed in the tail hair of horse P03. In this case, drug
administrations occurring 8 months before sampling
yielded a distinctive accumulation at a distance of 16–
18 cm from the skin (Fig. 2d). It should be noted that
flunixin concentrations were higher in tail (up to 3.3 pg/
mg) than in mane hair segments (below LLOQ). This
trend was confirmed by comparing flunixin residues in
the hair of horses P07 and P09 (data not shown).
Firocoxib was detected in the tail hair of horse P10 at
concentrations up to 5.0 pg/mg and at a distance of 12–
16 cm from the (Fig. 2e). This residue is due to firocoxib
treatments given 10 months before sampling.
Phenylbutazone administration was reported in six
horses, but the substance was detected in the hair of
only two of these animals. This is a consequence of
the relatively high LOD (10 pg/mg) linked to poor
ionization of phenylbutazone in the MS system. To
our knowledge, incorporation of phenylbutazone into
hair has not been described before. However, we were
able to detect this drug along the entire tail hair of
horse P06 with the highest concentration of 1300 pg/
mg at a distance of 52–56 cm from the skin. This
localization corresponds to a non-recorded treatment
that may have been carried out more than 2 years be-
fore sampling. Phenylbutazone was also detected in
the mane hair of horse P08 (Fig. 2f ). In this case, the
Fig. 1 LC-MS/MS chromatogram of a spiked sample with the respective MRM transitions for 13 investigated drugs
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observed localization pattern with a peak concentra-
tion of 3600 pg/mg in the 16–18-cm segment is ex-
plained with known phenylbutazone administrations
10 months before sampling. Finally, meloxicam was
detected in the tail hair of horse P02 at levels close
to the LLOQ (data not shown). Ketoprofen had been
administered in two cases but without leaving any
detectable residues in hair.
Table 4 Validation parameters: accuracy, intra-day and inter-day precision, matrix effects. N/A, not determined
Analyte QC sample Accuracy, bias (%) Intra-day precision,
SD (%)
Inter-day precision,
SD (%)
ME, mean ±
SD (%)
Morphine Low 0.6 6.2 8.8 56 ± 6.9
Medium 3.2 3.5 3.8 N/A
High −0.1 3.4 3.4 53 ± 9.8
Tramadol Low 2.4 4.3 5.2 107 ± 21
Med 0.4 4.5 4.5 N/A
High 4.9 1.8 2.3 183 ± 90
Detomidine Low 3.9 7.6 7.7 88 ± 24
Medium 5.9 7.7 9.1 N/A
High 2.9 4.5 5.9 79 ± 12
Butorphanol Low −0.4 10.2 15.2 87 ± 12
Medium 1.9 4.5 4.5 N/A
High −1.8 4.0 6.6 84 ± 10
Buprenorphine Low −9.3 4.5 8.0 87 ± 23
Medium −1.2 4.5 4.5 N/A
High −0.6 2.0 2.0 88 ± 7.7
Acepromazine Low 87 28 53 97 ± 31
Medium 8.3 8.2 11 N/A
High −0.7 11 11 117 ± 14
Firocoxib Low 4.7 3.0 6.7 82 ± 11
Medium 2.6 1.7 2.0 N/A
High 2.8 4.0 4.0 83 ± 8.7
Meloxicam Low 4.1 2.9 5.7 78 ± 12
Medium 4.2 3.1 5.2 N/A
High −4.1 3.1 3.5 70 ± 12
Chlorpromazine Low −3.5 3.2 6.3 77 ± 42
Medium 6.2 2.9 2.9 N/A
High 0.9 2.9 3.2 90 ± 41
Ketoprofen Low 6.1 5.6 7.0 78 ± 13
Medium −1.9 1.8 2.1 N/A
High 5.3 5.5 5.5 86 ± 12
Flunixin Low 5.8 5.8 7.3 89 ± 16
Medium 0.4 2.2 2.8 N/A
High 3.5 3.2 3.2 75 ± 7.0
Fluphenazine Low 7.3 5.6 14.8 92 ± 125
Medium 12.2 20 21 N/A
High 18.4 18.7 19.3 81 ± 51
Phenylbutazone Low 6.1 9.8 10.7 75 ± 14
Medium 1.2 4.4 6.1 N/A
High 2.3 4.6 6.2 60 ± 6.7
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Influence of pigmentation
The analyzed hair samples differed in color. The mane
and tail hair of horse P01 as well as the mane hair of
horse P09 were light and white, respectively, due to
their low melanin content. In view of the melanin-
dependent incorporation of basic drugs into hair (see
Discussion), it is not surprising to find that the light
hair of horse P01 was negative for all tested analytes
although acepromazine and phenylbutazone adminis-
trations had been documented. Notably, the white
mane hair of horse P09 (Fig. 3a) displayed only mode-
rately lower concentrations of flunixin than the corres-
ponding black tail hair of the same horse (Fig. 3b).
However, all examined hair segments contained flunixin
despite the fact that this drug was applied only 1 week
before sample collection. Flunixin incorporated via the
hair follicle could not yet have grown out as the follicle
is located a few millimeters below the epidermis. Thus,
the most likely explanation for the presence of flunixin
in mane and tail hair of this horse is an incorporation
via sweat and sebum [20].
Correlation between time of treatment and hair segment
Frequently, the analysis of mane or tail hair segments
revealed a clear peak of drug incorporation (see for ex-
ample Fig. 2b). In case of a broader distribution, as for
example in Fig. 2c, the median distance from the skin
was taken as the measure for drug localization. Subse-
quently, the assignments of drug localization in hair
were compared to the reported times of treatment
(Fig. 4). This relationship demonstrated that the time of
drug administration can be calculated by assuming an
average hair growth rate of 1.84 cm per month.
Discussion
The incorporation of a systemically administered drug
into hair is dependent on the melanin content and the
physicochemical properties of each substance [8, 21–23].
Basic drugs can reach 10-fold higher concentrations in
pigmented than in non-pigmented hair [8, 21–23]. In
contrast, no differences in hair incorporation were ob-
served for acidic compounds and, as a consequence, hair
concentrations of ketoprofen (pka = 4.45), meloxicam
Fig. 2 Drug localization patterns in the long hair of horses with documented treatments. a Distribution of butorphanol in tail hair 22 months
after treatment. b Distinctive peak of tramadol in mane hair 6 months after treatment. c Distribution of acepromazine in tail hair 15–16 months
after treatment. d Distribution of flunixin in tail hair 8 months after treatment. e Distribution of firocoxib in tail hair 10 months after treatment.
f Distribution of phenylbutazone in mane hair 10 months after treatment
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(pka = 4.05) or phenylbutazone (pka = 4.50) are low inde-
pendently of hair color [8].
Several further considerations are necessary for the
correct interpretation of hair findings. First, shifting of
single hair against each other during sampling should be
avoided to obtain the highest time resolution. Second,
external contamination has to be taken into account and
decontamination of hair samples is crucial. Third, one
must consider that a substance may not only be found
in the hair segment corresponding to the time of intake
but also in adjacent segments. This may especially be
the case when hair is cut into short segments of 1 to
2 cm length [8]. Fourth, the detection of substance in
hair segments grown before drug administration can be
explained by deposition mediated by sweat or sebum.
Finally, it takes time for a hair sample to become nega-
tive after drug administration has been ceased due to
the hair follicle proportion in the telogenic phase. In
addition, hair follicle activity is compromised by disease
or stressful events like anesthesia [24]. Decomposition
of incorporated drug due to exposure to UV light or
hair damage with drug leakage may account for nega-
tive findings [2].
Conclusion
In conclusion, the present fully validated LC-MS/MS
method offers a valuable tool for the retrospective tracking
of drugs as their detection in a hair segment proves previ-
ous medical treatments dating back up to 22 months be-
fore sampling. It was demonstrated that, particularly but
not exclusively, drugs with neutral or basic properties can
be monitored in dark long hair of horses. Further, our
study demonstrates that the time of drug administration
can be estimated based on an average growth rate of
1.84 cm per month. Further investigations should include
the analysis of metabolites. Moreover, it should be deter-
mined to what extent light hair displaying a low melanin
content could also be used for drug monitoring.
Abbreviations
LC-MS/MS, liquid chromatography tandem mass spectrometry; SoHT, society
of hair testing; QC, quality control; MRM, multiple reaction monitoring; LOD,
limit of detection; LLOQ, lower limit of quantification
Acknowledgments
The authors would like to thank the horse holders for providing horse hair
samples and Monique Fanger for her assistance.
Funding
The authors express their gratitude to Emma Louise Kessler, MD for her
generous legacy she donated to the Institute of Forensic Medicine at the
University of Zurich, Switzerland for research purposes.
Availability of data and materials
The datasets supporting the conclusions of this article are included within
the article.
Authors’ contributions
Sample collection, study design and documentation of drug administrations:
MMM, JK, AF. Method development and sample analysis: MMM, BS.
Interpretation, preparation of the manuscript: MMM, MRB, TK, JK. Initiation of
the study and final manuscript version: HN. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Fig. 3 Pattern of flunixin in hair of the same horse treated 1 week before sample collection. a Flunixin in white mane hair. b Flunixin in dark tail
hair. These findings reflect sweat- and sebum-mediated flunixin incorporation
Fig. 4 Drug localization in horse hair as a function of the time of
documented drug administrations. This graph shows the median
distance from skin and range of segments with clearly increased
drug incorporation. The slop of the resulting linear relationship is
consistent with an average growth rate of 1.84 cm per month
Madry et al. BMC Veterinary Research  (2016) 12:84 Page 9 of 10
Ethics approval and consent to participate
Hair samples were collected for diagnostic purposes from veterinary hospital
patients with owners’ consent. Therefore, the study did not need a formal
ethical approval based on the Swiss Animal Protection Act TSchV.
Author details
1Zurich Institute of Forensic Medicine, Center for Forensic Hair Analytics,
University of Zurich, Zurich, Switzerland. 2Zurich Institute of Forensic
Medicine, Center for Forensic Pharmacology and Toxicology, University of
Zurich, Zurich, Switzerland. 3Institute of Veterinary Pharmacology and
Toxicology, University of Zurich, Zurich, Switzerland. 4Clinic of Veterinary
Surgery, Department of Large Animal Surgery, University of Zurich, Zurich,
Switzerland.
Received: 23 October 2015 Accepted: 24 May 2016
References
1. Whittem T, Davis C, Beresford GD, Gourdie T. Detection of morphine in
mane hair of horses. Aust Vet J. 1998;76(6):426–7.
2. Dunnett M, Lees P. Trace element, toxin and drug elimination in hair with
particular reference to the horse. Res Vet Sci. 2003;75(2):89–101.
3. Schlupp A, Anielski P, Thieme D, Müller R, Meyer H, Ellendorff F. The β-agonist
clenbuterol in mane and tail hair of horses. Equine Vet J. 2004;36(2):118–22.
4. Anielski P, Thieme D, Schlupp A, Grosse J, Ellendorff F, Mueller RK. Detection
of testosterone, nandrolone and precursors in horse hair. Anal Bioanal Chem.
2005;383(6):903–8.
5. Boyer S, Garcia P, Popot MA, Steiner V, Lesieur M. Detection of testosterone
propionate administration in horse hair samples. J Chromatogr B. 2007;
852(1–2):684–8.
6. Kempson IM, Henry DA. Determination of Arsenic Poisoning and Metabolism
in Hair by Synchrotron Radiation: The Case of Phar Lap. Angew Chem Int Ed.
2010;49(25):4237–40.
7. Gray BP, Viljanto M, Bright J, Pearce C, Maynard S. Investigations into the
feasibility of routine ultra high performance liquid chromatography–tandem
mass spectrometry analysis of equine hair samples for detecting the misuse
of anabolic steroids, anabolic steroid esters and related compounds.
Anal Chim Acta. 2013;787:163–72.
8. Pragst F, Balikova MA. State of the art in hair analysis for detection of drug
and alcohol abuse. Clin Chim Acta. 2006;370(1–2):17–49.
9. Anielski P. Hair analysis of anabolic steroids in connection with doping
control—results from horse samples. J Mass Spectrom. 2008;43(7):1001–8.
10. Dunnett M. In: Pagan J, Geor RJ, editors. The diagnostic potential of equine
hair: a comparative review of hair analysis for assessing nutritional status,
environmental poisoning, and drug use and abuse. Advances in equine
nutrition-III. Kentucky: Kentucky Equine Research; 2005. p. 85–106.
11. Cooper G, Kronstrand R, Kintz P. Society of Hair Testing guidelines for drug
testing in hair. Forensic Sci Int. 2012;218(1–3):20–4.
12. Dunnett M, Lees P. Hair analysis as a novel investigative tool for the
detection of historical drug use/misuse in the horse: a pilot study.
Equine Vet J. 2004;36(2):113–7.
13. Jouvel C, Maciejewski P, Garcia P, Bonnaire Y, Horning S, Popot M-A.
Detection of diazepam in horse hair samples by mass spectrometric
methods. Analyst. 2000;125(10):1765–9.
14. Comin A, Veronesi MC, Montillo M, Faustini M, Valentini S, Cairoli F, et al.
Hair cortisol level as a retrospective marker of hypothalamic–pituitary–adrenal
axis activity in horse foals. Vet J. 2012;194(1):131–2.
15. Davis TZ, Stegelmeier BL, Hall JO. Analysis in Horse Hair as a Means of Evaluating
Selenium Toxicoses and Long-Term Exposures. J Agric Food Chem.
2014;62(30):7393–7.
16. SOFT/AAFS Forensic toxicology laboratory guidelines, Society of Forensic
Toxicologists/American Academy of Forensic Sciences (2006). http://www.
soft-tox.org/files/Guidelines_2006_Final.pdf. Accessed 29 May 2016.
17. Peters FT, Hartung M, Herbold M, Schmitt G, Daldrup T, Musshoff F. Appendix
B to the GTFCh Guidelines for Quality Assurance in Forensic-Toxicological
Analyses. Requirements for the validation of analytical methods. Toxichem
Krimtech. 2009;76:185.
18. Musshoff F, Skopp G, Pragst F, Sachs H. Appendix C of the GTFCh Guidelines
for Quality Control in Forensic-Toxicological Analyses. Quality requirements for
the analysis of hair samples. Toxichem Krimtech. 2009;76:209–16.
19. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment
of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS.
Anal Chem. 2003;75(13):3019–30.
20. Henderson GL. Mechanisms of drug incorporation into hair. Forensic Sci Int.
1993;63(1–3):19–29.
21. Pötsch L, Skopp G, Moeller M. Influence of pigmentation on the codeine
content of hair fibers in guinea pigs. J Forensic Sci. 1997;42:1095–8.
22. Nakahara Y, Takahashi K, Kikura R. Hair analysis for drugs of abuse. X. Effect
of physicochemical properties of drugs on the incorporation rates into hair.
Biol Pharm Bull. 1995;18(9):1223–7.
23. Gaillard Y, Pépin G. Testing hair for pharmaceuticals. J Chromatogr B Biomed
Sci Appl. 1999;733(1):231–46.
24. Rosychuk RAW. Noninflammatory, Nonpruritic Alopecia of Horses. Vet Clin N
Am Equine Pract. 2013;29(3):629–41.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Madry et al. BMC Veterinary Research  (2016) 12:84 Page 10 of 10
